> For the complete documentation index, see [llms.txt](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/apigenin-in-oncology.md). # Apigenin in Oncology ## Apigenin in Oncology ### What it is Apigenin is a plant flavone — a subclass of flavonoid polyphenol — found in parsley, celery, chamomile, dried oregano, vine spinach, and several citrus-adjacent herbs. It is a direct compound, not a precursor or metabolite. In foods, apigenin is usually present as glycosides bound to sugar molecules. The gut must first cleave those sugars to release free apigenin, the aglycone, before absorption into the bloodstream. Liposomal apigenin supplies the free aglycone in a pre-formulated carrier, reducing reliance on this gut conversion step and generally improving absorption efficiency. Apigenin is lipophilic and a weak acid. That helps it cross cell membranes more readily than many other flavonoids. ### Why it gets attention in oncology Apigenin keeps appearing in cancer research because it repeatedly pressures the BCL-2 family of anti-apoptotic proteins, especially MCL-1 and BCL-xL. These are the same survival proteins that help cancer cells resist chemotherapy and persist under stress. Beyond that, apigenin suppresses `STAT3`, `NF-κB`, and `PI3K/AKT/mTOR` signalling. It interferes with tumour metabolism through PKM2-linked glycolysis. It reduces pro-inflammatory SASP output from senescent stromal cells. It has also shown anti-metastatic effects across multiple animal models. Some models also show PD-L1 modulation, which creates tentative interest in immune-oncology settings. No other dietary flavone has quite this combination of BCL-2 family pressure, senomorphic activity, and broad pathway reach across so many tumour types. ### Key translational issue Oral bioavailability is the central bottleneck. Achieving pharmacologically meaningful tissue concentrations with conventional oral dosing is difficult. Calculated relative oral bioavailability is about 30%. Half-life is short, averaging roughly 2.5 hours. Doses that look active in most preclinical studies exceed what normal dietary intake can deliver. There is real formulation data showing improved exposure and stronger preclinical antitumour effects with liposomal delivery. That evidence remains formulation, animal, and in vitro work. It is not phase-based clinical oncology data. ### Clinical positioning All oncology work on apigenin remains preclinical or pharmacokinetic. No completed randomised human trials have tested apigenin against cancer outcomes. Today, apigenin is best positioned as a compound of serious mechanistic interest and a reasonable research-level adjunct candidate, especially in layered apoptosis-focused or senolytic-style strategies. The literature shows a consistent pattern. Apigenin lowers the apoptotic threshold in stressed, treatment-exposed, and senescent-like cells. It does this by lowering key survival proteins, especially `MCL-1` and `BCL-xL`, reinforcing p53-linked damage responses, and activating caspase-dependent mitochondrial pathways across multiple tumour types. {% hint style="warning" %} Apigenin is **not** a standard cancer treatment. The current case for it is mechanistic and preclinical, not clinically proven. {% endhint %} ### Explore this hub * [Evidence Summary](/myhealingcommunity-docs/natural-medicines/apigenin-in-oncology/evidence-summary.md) * [Anticancer Mechanisms](/myhealingcommunity-docs/natural-medicines/apigenin-in-oncology/anticancer-mechanisms.md) * [Immune Effects](/myhealingcommunity-docs/natural-medicines/apigenin-in-oncology/immune-effects.md) * [Synergistic Combinations](/myhealingcommunity-docs/natural-medicines/apigenin-in-oncology/synergistic-combinations.md) * [Apigenin Evidence by Cancer Type](/myhealingcommunity-docs/natural-medicines/apigenin-in-oncology/apigenin-evidence-by-cancer-type.md) * [Pharmacokinetics & Metabolism](/myhealingcommunity-docs/natural-medicines/apigenin-in-oncology/pharmacokinetics-and-metabolism.md) * [Safety & Interactions](/myhealingcommunity-docs/natural-medicines/apigenin-in-oncology/safety-and-interactions.md) * [Dosing & Timing](/myhealingcommunity-docs/natural-medicines/apigenin-in-oncology/dosing-and-timing.md) * [Sourcing Quality Apigenin](/myhealingcommunity-docs/natural-medicines/apigenin-in-oncology/sourcing-quality-apigenin.md) * [Terrain Support — SASP Suppression](/myhealingcommunity-docs/natural-medicines/apigenin-in-oncology/terrain-support-sasp-suppression.md) * [Sensitisation to Conventional Therapies](/myhealingcommunity-docs/natural-medicines/apigenin-in-oncology/sensitisation-to-conventional-therapies.md) ### Evidence quality rating * **Cell-line data:** Extensive. Signals are consistent across many cancer types. * **Animal data:** Strong and consistent, especially in colorectal, hepatocellular, prostate, and lung cancer. * **Human oncology data:** Absent. Human data are limited to pharmacokinetics and bioavailability. **Overall rating:** Serious preclinical interest. No human clinical proof. ### Strongest current discussion areas * **BCL-2 family modulation** — especially `MCL-1` and `BCL-xL` * **Chemosensitisation** to cisplatin, doxorubicin, `5-FU`, paclitaxel, and topoisomerase inhibitors * **Senomorphic activity** — suppression of the SASP in tumour-adjacent stromal cells * **Anti-metastatic effects** across melanoma, ovarian, prostate, and liver cancer models * **PD-L1 modulation** in melanoma models * **Advanced formulation development** — liposomal, nanoparticle, and SNEDDS approaches to bioavailability ### References * Liang Y, et al. [A Review on Flavonoid Apigenin: Dietary Intake, ADME, Antimicrobial Effects, and Interactions with Human Gut Microbiota](https://pmc.ncbi.nlm.nih.gov/articles/PMC6817918/) * Chmielewska M, et al. [Does Oral Apigenin Have Real Potential for a Therapeutic Effect in Cancer?](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.681477/full) * Yan X, et al. [Apigenin in cancer prevention and therapy: A systematic review and meta-analysis](https://www.sciencedirect.com/science/article/abs/pii/S1040842822001755) --- # Agent Instructions This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com. ## Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/apigenin-in-oncology.md?ask=&goal= ``` `ask` is the immediate question: it should be specific, self-contained, and written in natural language. `goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.